Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Saved in:
Bibliographic Details
Title: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
Authors: Jongbloed EM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Wortelboer N; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., de Weerd V; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Van MN; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Kraan J; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., van Zweeden AA; Department of Medical Oncology, Amstelland Hospital, Amstelveen, the Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands., Hamming LC; Department of Medical Oncology, Frisius MC Leeuwarden, Leeuwarden, the Netherlands., Konings IR; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. s.wilting@erasmusmc.nl.
Source: Nature medicine [Nat Med] 2025 Nov; Vol. 31 (11), pp. 3662-3667. Date of Electronic Publication: 2025 Sep 04.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-025-03935-w